503 related articles for article (PubMed ID: 11927615)
1. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut.
Kabashima K; Saji T; Murata T; Nagamachi M; Matsuoka T; Segi E; Tsuboi K; Sugimoto Y; Kobayashi T; Miyachi Y; Ichikawa A; Narumiya S
J Clin Invest; 2002 Apr; 109(7):883-93. PubMed ID: 11927615
[TBL] [Abstract][Full Text] [Related]
2. Comparison of prostaglandin E2 receptor subtype 4 agonist and sulfasalazine in mouse colitis prevention and treatment.
Jiang GL; Im WB; Donde Y; Wheeler LA
J Pharmacol Exp Ther; 2010 Dec; 335(3):546-52. PubMed ID: 20833794
[TBL] [Abstract][Full Text] [Related]
3. The prevention of colitis by E Prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration.
Jiang GL; Nieves A; Im WB; Old DW; Dinh DT; Wheeler L
J Pharmacol Exp Ther; 2007 Jan; 320(1):22-8. PubMed ID: 17008451
[TBL] [Abstract][Full Text] [Related]
4. MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis.
Araki A; Kanai T; Ishikura T; Makita S; Uraushihara K; Iiyama R; Totsuka T; Takeda K; Akira S; Watanabe M
J Gastroenterol; 2005 Jan; 40(1):16-23. PubMed ID: 15692785
[TBL] [Abstract][Full Text] [Related]
5. Role of EP4 receptor and prostaglandin transporter in prostaglandin E2-induced alteration in colonic epithelial barrier integrity.
Lejeune M; Leung P; Beck PL; Chadee K
Am J Physiol Gastrointest Liver Physiol; 2010 Nov; 299(5):G1097-105. PubMed ID: 20813914
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment with alanyl-glutamine suppresses T-helper-cell-associated cytokine expression and reduces inflammatory responses in mice with acute DSS-induced colitis.
Chu CC; Hou YC; Pai MH; Chao CJ; Yeh SL
J Nutr Biochem; 2012 Sep; 23(9):1092-9. PubMed ID: 22137260
[TBL] [Abstract][Full Text] [Related]
7. Expression of the EP4 prostaglandin E2 receptor subtype with rat dextran sodium sulphate colitis: colitis suppression by a selective agonist, ONO-AE1-329.
Nitta M; Hirata I; Toshina K; Murano M; Maemura K; Hamamoto N; Sasaki S; Yamauchi H; Katsu K
Scand J Immunol; 2002 Jul; 56(1):66-75. PubMed ID: 12100473
[TBL] [Abstract][Full Text] [Related]
8. Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis.
Esaki Y; Li Y; Sakata D; Yao C; Segi-Nishida E; Matsuoka T; Fukuda K; Narumiya S
Proc Natl Acad Sci U S A; 2010 Jul; 107(27):12233-8. PubMed ID: 20566843
[TBL] [Abstract][Full Text] [Related]
9. E prostanoid 2 (EP2)/EP4-mediated suppression of antigen-specific human T-cell responses by prostaglandin E2.
Okano M; Sugata Y; Fujiwara T; Matsumoto R; Nishibori M; Shimizu K; Maeda M; Kimura Y; Kariya S; Hattori H; Yokoyama M; Kino K; Nishizaki K
Immunology; 2006 Jul; 118(3):343-52. PubMed ID: 16827895
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic effects of Lonicera japonica extract on dextran sulphate sodium-induced colitis in a mouse model by the inhibition of the Th1/Th17 response.
Park JW; Bae H; Lee G; Hong BG; Yoo HH; Lim SJ; Lee K; Kim J; Ryu B; Lee BJ; Bae J; Lee H; Bu Y
Br J Nutr; 2013 Jan; 109(2):283-92. PubMed ID: 22569277
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin E receptor EP4 stimulates lymphangiogenesis to promote mucosal healing during DSS-induced colitis.
Hosono K; Kojo K; Narumiya S; Majima M; Ito Y
Biomed Pharmacother; 2020 Aug; 128():110264. PubMed ID: 32447215
[TBL] [Abstract][Full Text] [Related]
12. Prevention of trinitrobenzene sulfonic acid-induced experimental colitis by oral administration of a poly(lactic-coglycolic acid) microsphere containing prostaglandin E₂ receptor subtype 4 agonist.
Okamoto T; Uemoto S; Tabata Y
J Pharmacol Exp Ther; 2012 May; 341(2):340-9. PubMed ID: 22300734
[TBL] [Abstract][Full Text] [Related]
13. Dominant role of prostaglandin E2 EP4 receptor in furosemide-induced salt-losing tubulopathy: a model for hyperprostaglandin E syndrome/antenatal Bartter syndrome.
Nüsing RM; Treude A; Weissenberger C; Jensen B; Bek M; Wagner C; Narumiya S; Seyberth HW
J Am Soc Nephrol; 2005 Aug; 16(8):2354-62. PubMed ID: 15976003
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development.
Shoji Y; Takahashi M; Kitamura T; Watanabe K; Kawamori T; Maruyama T; Sugimoto Y; Negishi M; Narumiya S; Sugimura T; Wakabayashi K
Gut; 2004 Aug; 53(8):1151-8. PubMed ID: 15247185
[TBL] [Abstract][Full Text] [Related]
15. Effects of prostanoid EP agonists on mouse intraocular pressure.
Saeki T; Ota T; Aihara M; Araie M
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2201-8. PubMed ID: 19117925
[TBL] [Abstract][Full Text] [Related]
16. R-spondin1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice.
Zhao J; de Vera J; Narushima S; Beck EX; Palencia S; Shinkawa P; Kim KA; Liu Y; Levy MD; Berg DJ; Abo A; Funk WD
Gastroenterology; 2007 Apr; 132(4):1331-43. PubMed ID: 17408649
[TBL] [Abstract][Full Text] [Related]
17. Endogenous prostaglandin E2 accelerates healing of indomethacin-induced small intestinal lesions through upregulation of vascular endothelial growth factor expression by activation of EP4 receptors.
Takeuchi K; Tanigami M; Amagase K; Ochi A; Okuda S; Hatazawa R
J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S67-74. PubMed ID: 20586869
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E2 promotes wound-induced migration of intestinal subepithelial myofibroblasts via EP2, EP3, and EP4 prostanoid receptor activation.
Iwanaga K; Okada M; Murata T; Hori M; Ozaki H
J Pharmacol Exp Ther; 2012 Mar; 340(3):604-11. PubMed ID: 22138372
[TBL] [Abstract][Full Text] [Related]
19. Regulation of gut inflammation and th17 cell response by interleukin-21.
Fina D; Sarra M; Fantini MC; Rizzo A; Caruso R; Caprioli F; Stolfi C; Cardolini I; Dottori M; Boirivant M; Pallone F; Macdonald TT; Monteleone G
Gastroenterology; 2008 Apr; 134(4):1038-48. PubMed ID: 18395085
[TBL] [Abstract][Full Text] [Related]
20. Involvement of prostaglandin E receptor EP3 subtype in duodenal bicarbonate secretion in rats.
Aihara E; Nomura Y; Sasaki Y; Ise F; Kita K; Takeuchi K
Life Sci; 2007 Jun; 80(26):2446-53. PubMed ID: 17512019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
